| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Oncology Center [R. A. C., B. G., H. W. T., J. S., S. B. B.] and the Department of Medicine [S. B. B.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; and Wayne State University, Harper Hospital, Detroit, Michigan 48201 [G. D. L.]
Difluoromethylornithine (DFMO), an enzyme activated irreversible inhibitor of ornithine decarboxylase (ODC), depletes intracellular putrescine, and spermidine (Spd), but not spermine, and generally leads to an inhibition of cell proliferation, without cell death, in both normal and neoplastic cells. This is the case with a culture line of human large cell undifferentiated lung cancer, NCI H157, which will survive indefinitely in DFMO containing medium and ultimately actually grows through the DFMO block. We now provide evidence that a Spd analogue, N1,N8-bis(ethyl)spermidine (BES) also suppresses ODC activity in H157 cells but leads not only to complete depletion of putrescine and Spd but also reduces intracellular spermine to 2030% of control levels. This depletion of polyamines is accompanied by a rapid decrease in cell proliferation and ultimately cell death. The cell death resulting from BES treatment is in direct contrast to results obtained with DFMO and occurs at concentrations of less than 10 µM, whereas 5 mM DFMO is required to maintain growth inhibition in NCI H157. The observed suppression of ODC activity by BES is consistent with mechanisms by which Spd itself regulates ODC activity. Our data suggest that although both agents, DFMO and BES, interfere with polyamine metabolism, the differential sensitivities to these agents indicate susceptibility to polyamine depletion may be agent and cell type specific. Such differences may be related to the different requirement of individual cell types for polyamines and different regulatory events in polyamine biosynthesis. These differences may be exploitable in the treatment of neoplastic disease with polyamine analogues or inhibitors of polyamine biosynthesis.
1 This work was supported by NIH Grants CA37606, CA43280, CA09071, and AM27157.
2 To whom requests for reprints should be addressed, at The Johns Hopkins Oncology Center, 600 North Wolfe Street, Baltimore, MD 21205.
Received 12/10/86. Revised 2/27/87. Revised 5/ 5/87. Accepted 5/ 8/87.
This article has been cited by other articles:
![]() |
Y. Huang, E. Greene, T. Murray Stewart, A. C. Goodwin, S. B. Baylin, P. M. Woster, and R. A. Casero Jr Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes PNAS, May 8, 2007; 104(19): 8023 - 8028. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. L. Carlisle, W. L. Devereux, A. Hacker, P. M. Woster, and R. A. Casero Jr. Growth Status Significantly Affects the Response of Human Lung Cancer Cells to Antitumor Polyamine-Analogue Exposure Clin. Cancer Res., August 1, 2002; 8(8): 2684 - 2689. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Li, J. Li, J. N. Rao, M. Li, B. L. Bass, and J.-Y. Wang Inhibition of polyamine synthesis induces p53 gene expression but not apoptosis Am J Physiol Cell Physiol, April 1, 1999; 276(4): C946 - C954. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. C. Ha, P. M. Woster, J. D. Yager, and R. A. Casero Jr. The role of polyamine catabolism in polyamine analogue-induced programmed cell death PNAS, October 14, 1997; 94(21): 11557 - 11562. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |